EU Pharmacopoeia Meets New Milestone: Ends General Animal Safety Tests

General chapters on pyrogens, histamine and depressor substances – involving tests on rabbits, guinea pigs and cats – are being removed from the Ph. Eur, marking another step in the European Pharmacopoeia Commission’s ongoing efforts to replace, reduce and refine the use of animals for monograph requirements.

Cute Little Guinea Pig
The EPC has taken a big step forward in efforts to replace, reduce and refine the use of animals for monograph requirements (Shutterstock)
Key Takeaways
  • Chapters on pyrogens, histamine and depressor substances – which all involve animal tests – will no longer feature in the European Pharmacopoeia (Ph. Eur) as of its 12th edition.
  • The 12th Edition of the Ph. Eur will be published in July 2025, and enter into force in January 2026.
  • Measures to revise texts in the Ph. Eur omitting the rabbit pyrogen test and to adopt a new chapter on pyrogenicity were published last year, with an implementation date of 1 July 2025.

All general animal safety tests are being abolished from the European Pharmacopoeia (Ph. Eur), in a move that marks another significant milestone in the elimination of animal tests from the pharmacopoeia.

Following the European Pharmacopoeia Commission’s decision last June to remove from the Ph. Eur all references to the general chapter on pyrogens (2.6.8), which describes the rabbit pyrogen test (RPT), chapter 2.6.8 is now being removed entirely.

In addition, two other general chapters involving animal testing are also being removed from the Ph. Eur. These are the chapters on histamine (2.6.10) – which uses guinea pigs – and depressor substances (2.6.11) – which uses cats.

Furthermore, 14 monographs are being revised to delete either the reference to the histamine chapter or the requirement to eliminate or minimize substances that lower blood pressure.

Chapters 2.6.8, 2.6.10 and 2.6.11 will no longer feature in the Ph. Eur as of its 12th edition, which will be published in July 2025, and enter into force in January 2026.

Together with the suppression of the general chapter on abnormal toxicity (2.6.9) in 2017, the EPC has now abolished all general animal safety tests in the Ph. Eur, said the European Directorate for the Quality of Medicines & HealthCare (EDQM), which last month announced the EPC’s decision to remove the latest three chapters.

The directorate noted that the animal tests involved had been present in the Ph. Eur for many years to ensure the safety of parenteral medicines, before the development of the modern analytical techniques that are now available and good manufacturing practice conditions.

It said the suppression of the latest three chapters was in accordance with the European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes, and was another step in the EPC’s ongoing efforts to replace, reduce and refine (3R principles) the use of animals for monograph requirements.

When the EPC decided to remove the RPT from its monographs last June, its Swiss delegation said the move was “a significant step forward in terms of animal welfare,” and would “send out a strong message across the world.”

Medicine developers were told that they would be responsible for selecting a suitable in vitro test to control the pyrogenicity of their product.

Pyrogens

The removal of the general chapter on pyrogens follows the EPC’s adoption last June of 57 revised texts in the Ph. Eur from which the RPT was deleted, and a new general chapter on pyrogenicity (5.1.13).

The revised texts omitting the RPT and the newly adopted chapter on pyrogenicity were published in supplement 11.8 of the Ph. Eur, with an implementation date of 1 July 2025.

The EDQM said it would be the responsibility of medicine developers to select a suitable in vitro test (eg, the monocyte-activation test) to control the pyrogenicity of their product, based on a risk assessment as described in the new general chapter.

Pyrogens are fever-inducing contaminants that may unintentionally be present in medicines administered by injection (including vaccines, blood products, radiopharmaceuticals, antibiotics and large volume solutions for infusion). Their detection is therefore essential to ensure that medicines administered by this route are safe.

Histamine & Depressor Substances

The chapters on histamine and depressor substances describe tests that measure the effect of histamine and histamine-like substances.

The EDQM pointed to a Histamine Strategy Paper published last year that concluded that histamine and depressor substance animal tests were outdated, non-specific, not reproducible and not in line with the 3R policy.

“They were added to many monographs as safety tests before GMP and modern purification techniques were in place,” the paper said. “From the very start of elaboration of these monographs, 60 years ago, the relevance of these biological tests has been questioned and the absence of positive batches has been a trigger to delete these tests. However, the references to histamine or depressor substances have remained in texts, providing a false sense of safety to certain users.”

More from Drug Safety

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By 

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.

US FDA Asks Adcomm If Opioid Postmarketing Studies Are Relevant, Warrant Action

 
• By 

Two US FDA advisory committees will discuss results from epidemiological studies that attempted to quantify the prevalence, incidence and risk factors for misuse, abuse, overdose and death with opioid analgesics.

More from Geography

Life After Loper: Vaping Case Shows US FDA Retains Considerable Deference

 
• By 

A US Supreme Court ruling in favor of the agency in an e-cigarette case has implications for drugs and other medical products as the justices decided not to disturb the FDA’s ‘change in position’ authority, while also creating a complex new landscape.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.